title: Recurrence of IgG4-related disease following treatment with rituximab.
abstract: A 54-year-old woman with suspected low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type of the eyelids underwent rituximab-containing chemotherapy. She initially responded to the rituximab therapy, but later experienced two recurrences over a 3-year period. Biopsy specimens and a review of her previous histology revealed that she had had immunoglobulin G4-related disease at the initial presentation. Although IgG4-related disease seems to respond well to rituximab therapy, long-term follow up, including disease monitoring, is needed to evaluate disease remission.
authors.affiliation: Department of Internal Medicine (3), Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan, jmura-tym@umin.ac.jp.
authors.forename: Jun
authors.initials: J
authors.lastname: Murakami
authors.forename: Shoko
authors.initials: S
authors.lastname: Matsui
authors.forename: Shin
authors.initials: S
authors.lastname: Ishizawa
authors.forename: Kotaro
authors.initials: K
authors.lastname: Arita
authors.forename: Akinori
authors.initials: A
authors.lastname: Wada
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Miyazono
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hounoki
authors.forename: Koichiro
authors.initials: K
authors.lastname: Shinoda
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Taki
authors.forename: Toshiro
authors.initials: T
authors.lastname: Sugiyama
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D000069283:Rituximab